Clinical Trial Update: B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating B7-H3 CAR T cells (B7-H3CART) for recurrent glioblastoma multiforme is currently recruiting, sponsored by Stanford Universit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• B7-H3 CAR T cells (B7-H3CART) (B7-H3 CAR T cells)

Snippet

Sponsor: Stanford University | Conditions: Brain and Nervous System | Phase 1 | Status: RECRUITING